Millennium Management
CARM

Millennium Management’s Carisma Therapeutics CARM Stock Holding History

Millennium Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-120,157
Closed -$50.3K – 5903
2024
Q4 		$50.3K Sell
120,157
-22,365
-16% -$18.4K ﹤0.01% 5592
2024
Q3 		$140K Sell
142,522
-17,519
-11% -$19K ﹤0.01% 5527
2024
Q2 		$243K Buy
+160,041
New +$239K ﹤0.01% 5035
2023
Q2 		– Sell
-35,673
Closed -$111K – 6152
2023
Q1 		$111K Sell
35,673
-16,085
-31% -$153K ﹤0.01% 5388
2022
Q4 		$631K Sell
51,758
-8,982
-15% -$94.3K ﹤0.01% 4562
2022
Q3 		$516K Sell
60,740
-73,202
-55% -$997K ﹤0.01% 4951
2022
Q2 		$2.17M Buy
+133,942
New +$1.53M ﹤0.01% 3623
2022
Q1 		– Sell
-718
Closed -$12K – 6944
2021
Q4 		$12K Sell
718
-29,518
-98% -$594K ﹤0.01% 6637
2021
Q3 		$480K Sell
30,236
-57,689
-66% -$2.77M ﹤0.01% 5389
2021
Q2 		$8.12M Buy
87,925
+6,680
+8% +$426K 0.01% 2161
2021
Q1 		$4.22M Buy
81,245
+49,396
+155% +$2.33M ﹤0.01% 2768
2020
Q4 		$860K Buy
+31,849
New +$808K ﹤0.01% 3829
2020
Q1 		– Sell
-5,076
Closed -$106K – 3899
2019
Q4 		$106K Buy
+5,076
New +$117K ﹤0.01% 4020
2019
Q2 		– Sell
-2,222
Closed -$46K – 4079
2019
Q1 		$46K Sell
2,222
-52,773
-96% -$911K ﹤0.01% 3900
2018
Q4 		$1.56M Buy
54,995
+13,493
+33% +$430K ﹤0.01% 2350
2018
Q3 		$1.78M Buy
+41,502
New +$1.62M ﹤0.01% 2513
2018
Q2 		– Sell
-12,263
Closed -$258K – 3810
2018
Q1 		$258K Buy
+12,263
New +$235K ﹤0.01% 3268
2016
Q4 		– Sell
-3,955
Closed -$222K – 3353
2016
Q3 		$222K Buy
+3,955
New +$294K ﹤0.01% 2937
2016
Q1 		– Sell
-1,814
Closed -$109K – 3279
2015
Q4 		$109K Sell
1,814
-171
-9% -$9.71K ﹤0.01% 3229
2015
Q3 		$96K Buy
1,985
+687
+53% +$42.3K ﹤0.01% 3279
2015
Q2 		$73K Buy
+1,298
New +$183K ﹤0.01% 3203

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $58.1B AUM 27.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management's CARM Position: Q1 2025 in Review

Millennium Management sold out of Carisma Therapeutics (CARM) in Q1 2025, closing a stake of 120,157 shares — an estimated $50.3K sold.

Millennium Management first reported a position in CARM in Q2 2015 and held it in 21 quarters. The position peaked at $8.12M in Q2 2021. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2025.

  • Millennium Management reported no remaining Carisma Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Millennium Management sold 120,157 Carisma Therapeutics shares in Q1 2025, an estimated $50.3K.
  • Millennium Management first reported a position in Carisma Therapeutics in Q2 2015 and held it in 21 quarters.
  • Millennium Management's Carisma Therapeutics position peaked at $8.12M in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.